Kura Oncology (KURA) Enterprise Value (2010 - 2026)

Kura Oncology (KURA) has 17 years of Enterprise Value data on file, last reported at -$580.8 million in Q1 2026.

• On a quarterly basis, Enterprise Value rose 11.75% year-over-year to -$580.8 million in Q1 2026; TTM through Mar 2026 was -$580.8 million, a 11.75% increase from a year earlier, with the FY2025 full-year figure at -$667.2 million, up 8.27% from the prior year.
• Enterprise Value for Q1 2026 stood at -$580.8 million, up from -$667.2 million in the prior quarter.
• Over the last five years, Enterprise Value for KURA reached as high as -$405.9 million in Q1 2023 and fell as low as -$727.4 million in Q4 2024.
• Historically, Enterprise Value has averaged -$520.2 million across 5 years, with a median of -$480.1 million in 2022.
• Across the five-year window, Enterprise Value gained 21.28% in 2022 and plunged 71.57% in 2024, its largest moves.
• Year by year, Enterprise Value stood at -$438.0 million in 2022, then advanced by 3.2% to -$424.0 million in 2023, then plunged by 71.57% to -$727.4 million in 2024, then advanced by 8.27% to -$667.2 million in 2025, then grew by 12.95% to -$580.8 million in 2026.
• Per Business Quant data, the three most recent Enterprise Value figures were -$580.8 million in Q1 2026, -$667.2 million in Q4 2025, and -$549.7 million in Q3 2025.